Prostate Cancer Survival Rates Jump with Drug โCombination, Majorโ Studyโค Finds
LOS ANGELES, CA – A new eight-year study fromโข teh โCedai-Sinar Cancer Center in Los Angeles reveals a significant improvement in survival rates โฃfor men with cancer-music/” title=”Rage Against The Machine Bassist Fights Prostate … | Music”>prostate cancer โคwhen treated with โaโข combination of the drugs enzalutamide โadnโฃ leuprolide. Theโ findings, published and reported โby New Atlas, offer a potential breakthrough โขin combating the disease,โฃ particularly in cases where โcancer returns after initial treatment.
Approximately 40% โฃof men experience โprostate cancer recurrence following first-line therapies, often with โคa more aggressive form of the disease.”After a โขfirst treatment, some patientsโ see their prostate cancer return aggressively and risk that the disease spreadsโ quickly,” explained a co-author of the study.
The research, involving over 1,000 participants from 17 countries,โ divided patients into three โgroups: one receiving enzalutamide,โค another โreceiving leuprolide, and a third receiving both โdrugs concurrently. While the first two groups showed no significant improvement, the combination therapy demonstrated aโ 40.3% increase โฃin survival rates after an average of eight years of follow-up.
Importantly,โ bothโ enzalutamide and leuprolide are already approved for use in prostate cancer treatment by the Food and Drug administrationโฃ in the United States. Researchers anticipateโค these results will โฃexpedite the approval process โขfor the โcombined therapy, offering a potentially โlife-saving โขoption โfor โคa wider โrange of patients.